🔎 Trials Near Me

Почетна › Немалоклетни карцином плућа › Merilend

Kliničke studije za Немалоклетни карцином плућа u državi Merilend

75 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u državi Merilend.

Gradovi u državi Merilend

Zvanični tekst studije (na engleskom)

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • UM Upper Chesapeake Hematology and Oncology - Aberdeen, Aberdeen
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • UPMC Western Maryland, Cumberland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Luminis Health Anne Arundel Medical Center, Annapolis
  • Greater Baltimore Medical Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • и још 9
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

  • National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студија
Узраст од 18 до 120 · Оба пола · Ажурирано 12. 11. 2026. · NCT02682667

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  • Ascension Saint Agnes Hospital, Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06472245

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • Johns Hopkins University, Baltimore
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07020221

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  • Local Institution - 0503, Baltimore
  • Local Institution - 0537, Baltimore
  • Local Institution - 0523, Silver Spring
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07680790

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, Baltimore
  • Research Site, Brandywine
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07291037

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  • National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 1
Узраст од 18 до 120 · Оба пола · Ажурирано 10. 11. 2026. · NCT06066138

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  • Maryland Oncology Hematology (MOH) ( Site 8102), Rockville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06623422

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  • Velocity Clinical Research, Annapolis, Annapolis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06561386

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • Maryland Oncology Hematology, P.A., Annapolis
  • Maryland Oncology Hematology, P.A., Bethesda
  • Maryland Oncology Hematology, PA, Brandywine
  • и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07144280

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06793215

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • University of Maryland, Baltimore
  • Johns Hopkins Bayview Medical Center, Baltimore
  • James M Stockman Cancer Institute, Frederick
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06890598

Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

  • University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07746388

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Maryland Oncology Hematology, Rockville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • Christiana Care - Union Hospital, Elkton
  • и још 3
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Johns Hopkins Bayview Medical Center, Baltimore
  • USO - Maryland Oncology Hematology, Columbia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06119581

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • University of Maryland, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06667076

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  • Sidney Kimmel Cancer Center - Bayview Campus, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05498428

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  • Frederick Health Hospital- James M Stockman Cancer Institute, Frederick
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06712316

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT04613596

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

  • National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 2
Узраст од 18 до 72 · Оба пола · Ажурирано 30. 10. 2026. · NCT03412877

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA11-0, Bethesda
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06953089

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  • University of Maryland, Baltimore
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT05098132

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Bethesda
  • Research Site, Bethesda
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06692738

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  • Research Site, Baltimore
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06996782

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  • Research Site, Annapolis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06357533

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • University of Maryland Medical Center, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT05168566

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  • Velocity Clinical Research, Annapolis, Annapolis
  • Maryland Oncology Hematology - Columbia, Columbia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06875310

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Johns Hopkins University, Baltimore
  • Maryland Oncology Hematology, PA, Rockville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06172478

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT02984761

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Local Institution - 0123, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07680764

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07154290

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Baltimore
Тражи се учесникФаза 2
Узраст од 18 до 95 · Оба пола · Ажурирано 21. 10. 2026. · NCT05061550

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  • National Institutes of Health Clinical Center, Bethesda
Тражи се учесникФаза 2
Узраст од 18 до 72 · Оба пола · Ажурирано 20. 10. 2026. · NCT02133196

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

  • MedStar Franklin Square Medical Center ( Site 0033), Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06731907

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

  • National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT02146170

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

  • Research Site, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT07098338

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

  • University of Maryland, Baltimore
Тражи се учесникФаза 3
Узраст од 18 до 100 · Оба пола · Ажурирано 13. 10. 2026. · NCT05317858

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Kaiser Permanente-Woodlawn Medical Center, Baltimore
  • Kaiser Permanente-Gaithersburg Medical Center, Gaithersburg
  • Kaiser Permanente - Largo Medical Center, Largo
  • и још 1
Тражи се учесникФаза 2
18 Minutes · Оба пола · Ажурирано 9. 10. 2026. · NCT06031688

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.